Keyhole surgery for childhood neuroblastoma
Part of Cancer clinical trials.
This study looks at using keyhole (laparoscopic) surgery to remove neuroblastoma tumors in children. It groups tumors by risk factors to see which children can safely have this less invasive surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have a neuroblastoma (a tumor starting in nerve cells) that fits into one of the three study groups based on tumor size, location, and risk factors.
- Your child must be between 0 and 18 years old.
- Your child must have had a special CT scan (with contrast) within 14 days before the planned surgery to help plan the operation.
- A team of experts must have decided that surgery is the best option for your child.
- You (and your child, if old enough) must sign a form saying you understand the study and agree to take part.
- Your child cannot have certain very high-risk tumor features (like many risk factors plus a central location or large size) that would make keyhole surgery too risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This trial tests a personalized treatment plan for children with high-risk neuroblastoma, a type of nerve tissue cancer. It aims to improve outcomes by tailoring therapy based on each child's tumor characteristics and response to prior treatment.
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.